Jim is a business and financial writer, who had spent almost his entire life independently reporting on different business ventures with major impact on the US and global economy. Jim places a special focus on examining IPO potentials, tech stocks, biotech stocks all while investing a great part of his early hours to researching and writing on the companies in the US markets. Jim has 10+ years of experience in financial markets.
Silvergate Capital (NYSE:SI) may be a stock that appears to be undervalued and offer a great opportunity for investors. However, a closer examination of the company and its recent activities…
Investing in PayPal (PYPL) stock has become increasingly attractive over the past several months, as the company has seen a surge in share price and investor attention. PayPal has long…
ReShape Lifesciences (RSLS) is an innovative health solutions company that helps consumers and healthcare providers address obesity and chronic diseases. The company has developed a portfolio of products, programs, and…
Hoth Therapeutics (HOTH) saw its stock prices surge today, December 27, 2022, after the company announced that the U.S. Food and Drug Administration (FDA) had accepted its Investigational New Drug…
Nvidia (NVDA) stock went down sharply today, with shares dropping by more than 3% in early trading and 1.9% by the end of the day. This sudden decline may come…
Are you looking for a way to lose weight fast and naturally? Have you heard of Ikaria Lean Belly Juice? Here at Ikaria Health, we’ve done our own research on…
Are you looking for a safe and natural way to improve your overall health and wellbeing (hint: The Red Boost Hard Wood Tonic System)? Have you been searching for a…
MediWound’s NexoBrid is a topical burn treatment that could potentially revolutionize how severe burns are treated. It is a safe and effective way to remove damaged tissue from severe thermal…
Coherus BioSciences (CHRS) and Junshi Bioscience have recently submitted a resubmission of their BLA (Biologics License Application) to the FDA (Food and Drug Administration) for their cancer PD-1 inhibitor Toripalimab.…
Phantom Pharmaceuticals (NASDAQ: PHAT) recently announced that its drug, Vonoprazan, has been granted priority review by the U.S. Food and Drug Administration (FDA). Vonoprazan is a novel proton pump inhibitor…